Nicholas Paoni
44Patents
12h-index
47Co-inventors
77Inventor score
Filing activity: Jul 24, 1989 → Aug 23, 2002
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6635468B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Emerging Cross-Sectional Technologies | 66 | Expired |
| US7390879B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Chemistry; Metallurgy | 36 | Expired |
| US6936436B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Chemistry; Metallurgy | 32 | Expired |
| US7026448B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Chemistry; Metallurgy | 30 | Expired |
| US5108901A | Tissue plasminogen activator having zymogenic or fibrin specific properties | Human Necessities | 26 | Expired |
| US7074592B2 | Secreted and transmembrane polypeptides nucleic acid encoding | Chemistry; Metallurgy | 25 | Expired |
| US6974689B1 | Nucleic acid encoding PRO211 polypeptides | Chemistry; Metallurgy | 24 | Expired |
| US5262170A | Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells | Human Necessities | 18 | Expired |
| US5612029A | Tissue plasminogen activator glycosylation variants with improved therapeutic properties | Human Necessities | 17 | Expired |
| US5661122A | Treatment of congestive heart failure | Human Necessities | 16 | Expired |
| US5837241A | Method of treating heart failure using leukemia inhibitory factor antagonists optionally with endothelin antagonists | Human Necessities | 13 | Expired |
| US7189529B2 | PRO792 nucleic acids | Chemistry; Metallurgy | 12 | Expired |
| US7098312B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Chemistry; Metallurgy | 12 | Expired |
| US5405771A | Tissue plasminogen activator having zymogenic or fibrin specific properties | Human Necessities | 12 | Expired |
| US5616486A | Tissue plasminogen activator having zymogenic or fibrin specific properties | Human Necessities | 11 | Expired |
| US5520913A | Tissue plasminogen activator having zymogenic properties | Human Necessities | 10 | Expired |
| US7094567B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Emerging Cross-Sectional Technologies | 10 | Expired |
| US7026449B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Physics | 10 | Expired |
| US7033786B2 | Pro1340 nucleic acids | Chemistry; Metallurgy | 9 | Expired |
| US5573762A | Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy | Human Necessities | 9 | Expired |
| US7056736B2 | Secreted and transmembrane polypeptides and nucleic acids encoding the same | Emerging Cross-Sectional Technologies | 9 | Expired |
| US5411871A | Method for identifying tissue plasminogen activator having zymogenic or fibrin specific properties | Human Necessities | 7 | Expired |
| US5610134A | Treatment of congestive heart failure | Human Necessities | 7 | Expired |
| US6156733A | Use of leukemia inhibitory factor and endothelin antagonists | Human Necessities | 6 | Expired |
| US6187304A | Effects of IFN-.gamma. on cardiac hypertrophy | Human Necessities | 6 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.